Studies have demonstrated that SAC improved liver disease via regulation of the peroxisomal proliferator activator receptor α (PPAR-α), sterol regulatory element binding protein 1c (SREBP-1c), serum adiponectin levels, liver MDA, reactive oxygen species (ROS) content, serum ALT, serum AST, GSH content, GSH-Px and CAT activities, and the inhibition of lipolysis. This evidence concerns the gene SREBF1 and liver disorder.